Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) have received an average rating of “Buy” from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $8.80.
PYXS has been the topic of several research reports. Jefferies Financial Group reissued a “buy” rating and issued a $10.00 target price on shares of Pyxis Oncology in a research report on Tuesday, May 7th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research note on Thursday, May 16th.
Get Our Latest Analysis on PYXS
Institutional Inflows and Outflows
Pyxis Oncology Stock Up 7.4 %
PYXS opened at $3.48 on Tuesday. Pyxis Oncology has a twelve month low of $1.35 and a twelve month high of $6.85. The firm has a 50 day moving average price of $3.54 and a 200-day moving average price of $4.09. The stock has a market capitalization of $204.94 million, a price-to-earnings ratio of -2.56 and a beta of 1.28.
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last released its quarterly earnings results on Saturday, May 11th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.19. The firm had revenue of $16.15 million for the quarter, compared to the consensus estimate of $4.25 million. As a group, analysts expect that Pyxis Oncology will post -1.09 earnings per share for the current year.
About Pyxis Oncology
Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Featured Stories
- Five stocks we like better than Pyxis Oncology
- 3 Small Caps With Big Return Potential
- Why This AI Stock is Rising Despite Tech Sell-Off
- How to Use the MarketBeat Excel Dividend Calculator
- Investors Are Moving into Bonds and Small Cap Stocks: Here’s Why
- How to Calculate Return on Investment (ROI)
- MarketBeat Week in Review – 7/15 – 7/19
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.